PATENT AND TECHNOLOGY ASSIGNMENT AGREEMENTPatent and Technology Assignment Agreement • October 25th, 2011 • RXi Pharmaceuticals Corp • Massachusetts
This Patent and Technology Assignment Agreement (“AGREEMENT”), is by and between ADVIRNA, LLC, a Colorado limited liability company having its principal place of business at 10 Rocklawn Road, Westborough, MA 01581 (“ADVIRNA”) and RXi Pharmaceuticals Corporation (formerly RNCS, Inc.), a Delaware corporation, having its principal place of business at 60 Prescott Street, Worcester, MA 01605 (“RXi”). ADVIRNA and RXi may each be referred to as a “PARTY” and collectively as the “PARTIES”. For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the PARTIES agree as follows:
Text Marked By [* * *] Has Been Omitted Pursuant To A Request For Confidential Treatment And Was Filed Separately With The Securities And Exchange Commission. NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • October 25th, 2011 • RXi Pharmaceuticals Corp • Massachusetts
This Agreement, effective as of April 15, 2003 (the “Effective Date”), is between the University of Massachusetts Medical School (“Medical School”), a public institution of higher education of the Commonwealth of Massachusetts having an address of 55 Lake Avenue North, Worcester, MA 01655 and CytRx Corporation (“Company”), a Delaware corporation having an address of 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049.
June 9, 2011RXi Pharmaceuticals Corp • October 25th, 2011
This letter is to serve as an amendment to the Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC dated September 25, 2007 and later amended on August 28, 2008 and again on January 23, 2009.
D’Anne Hurd Vice President and General Counsel Vice President for Business Development at Gateway Park 100 Institute Road • Worcester, MA 01609-2280 Phone: 508 831-5072 • Fax: 508 831-6530 e-mail: dhurd@wpi.eduRXi Pharmaceuticals Corp • October 25th, 2011
Per the discussions with Eric Overstrom, Director of the WPI Life Sciences and Bioengineering Center (Newgate Properties, LLC), this letter is to serve as an amendment to the Lease between RXi Pharmaceuticals Corporation and Newgate Properties, LLC dated September 25, 2007.
